- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: example 39 [WO2013130976] | GDC-0994
Compound class: Synthetic organic
Comment: Ravoxertinib (GDC-0994) is an orally available, small molecule selective inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2) in early clinical development . It is compound 22 in . ERK1 is formally known as mitogen-activated protein kinase 3 (MAPK3) and ERK2 as mitogen-activated protein kinase 1 (MAPK1). GDC-0994 is example 39 claimed in patent WO2013130976 .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Blake JF, Burkard M, Chan J, Chen H, Chou KJ, Diaz D, Dudley DA, Gaudino JJ, Gould SE, Grina J et al.. (2016)
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
J Med Chem, 59 (12): 5650-60. [PMID:27227380]
2. Blake JF, Chicarelli MJ, Garrey RF, Gaudino J, Grina J, Moreno DA, Mohr PJ, Ren L, Schwarz J, Chen H et al.. (2013)
Serine/threonine kinase inhibitors.
Patent number: WO2013130976. Assignee: Array Biopharma Inc., Genentech, Inc.. Priority date: 01/03/2012. Publication date: 06/09/2013.